Navigation Links
Treatment over a longer period for blood clotting

Venous thromboembolism is a condition which causes clotting in the veins. Typical therapy for venous thromboembolism includes a five- to 10-day course of heparin followed by three to 12 months of the oral drug warfarin. However, the problem with this treatment is that once the patient goes off warfarin, venous thromboembolism recurs. While recurrence rates of this problem are reduced if the patient stays on warfarin, according to previous studies, it// also puts the patient at an increased risk for a major hemorrhage. Researchers have now conducted a study to find out whether keeping patients on a low-dose of warfarin would be beneficial or too much of a risk.

The study included more than 500 patients who received standard treatment and then were assigned to receive a placebo or low-intensity warfarin. Participants were followed to see who had recurrent venous thromboembolism, major hemorrhage, and who died. After four years, researchers found that 37 of the 253 patients assigned to the placebo had recurrent venous thromboembolism, as compared with 14 of the 255 patients on the low-intensity warfarin. This indicated a risk reduction of 64 percent. Furthermore, major hemorrhage occurred in two patients on the placebo and five on the warfarin. Researchers claimed that the reduction in the risk of recurrent venous thromboembolism for patients on low-intensity warfarin, after adjusting for other factors, was between 76 percent and 81 percent.

Andrew Schafer, M.D., from the University of Pennsylvania School of Medicine, in an accompanying editorial said that though researchers claim short-term treatment reduces the risk of recurrent venous thromboembolism by up to 81 percent, doctors are continuing to walk a tightrope for dosing medicine for patients with venous thromboembolism. Although low-intensity warfarin may prevent recurrent venous thromboembolism it is unclear what dosage doctors need to give to prevent recurrence and not cause major bleedin g.


'"/>




Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
(Date:6/24/2016)... ... , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event ... that have been wounded in battle and their families. Venture Construction Group is a ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... startling report released today, National Safety Council research shows ... plan to eliminate prescription opioid overdoses. Prescription Nation ... the worst drug crisis in recorded U.S. history, assigned a "Making ... , New Mexico , Tennessee ... states, three – Michigan , Missouri ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: